Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07175038 · ClinicalTrials.gov registry record · Phase 2

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

A Phase 2 study of Pulmonary Arterial Hypertension PAH and Pulmonary Hypertension, Interstitial Lung Disease, sponsored by AllRock Bio.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
11
Study locations

NCT07175038 is a Phase 2 study of Pulmonary Arterial Hypertension PAH and Pulmonary Hypertension, Interstitial Lung Disease that is actively recruiting participants, run by AllRock Bio. The registered enrollment target is 40 participants, roughly in line with the 40-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target. The trial reports 11 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07175038, a Phase 2 study of Pulmonary Arterial Hypertension PAH and Pulmonary Hypertension, Interstitial Lung Disease, is actively recruiting participants, sponsored by AllRock Bio.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
11
Study locations

Study Summary

This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by a long-term extension period of the study through the end of the program or marketing approval/authorization.

Conditions Studied

Pulmonary Arterial Hypertension PAH Pulmonary Hypertension, Interstitial Lung Disease

Interventions

  • DRUG ROC-101

Study Locations (11)

Arizona

  • Arizona Pulmonary Specialists - Phoenix

Colorado

  • University of Colorado - Aurora

Florida

  • Mayo Clinic of Florida - Jacksonville

Kansas

  • The University of Kansas Medical Center Research Institute - Kansas City

Michigan

  • University of Michigan - Ann Arbor

Ohio

  • Ohio State University - Columbus

Oregon

  • Bend Memorial Clinic - Bend

Pennsylvania

  • Temple University - Philadelphia

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-10-01
Est. Completion 2029-03
Phase Phase 2

Sponsor

AllRock Bio

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07175038

The ClinicalTrials.gov registry entry for NCT07175038 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 40-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target. The listed sponsor is AllRock Bio, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pulmonary Arterial Hypertension PAH appearing as the primary indexed condition, and to 1 intervention - of which ROC-101 is the first listed.

NCT07175038 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Arizona, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT07175038 about?

NCT07175038 is a clinical study titled "A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)". This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by ...

What is the current status of trial NCT07175038?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-10-01. Estimated completion is 2029-03.

What conditions does trial NCT07175038 study?

This clinical trial studies the following conditions: Pulmonary Arterial Hypertension PAH, Pulmonary Hypertension, Interstitial Lung Disease.

What interventions are being tested in trial NCT07175038?

The interventions under investigation include: ROC-101 (DRUG).

Who is sponsoring clinical trial NCT07175038?

This trial is sponsored by AllRock Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07175038 being conducted?

This trial has 11 study locations across Arizona, Colorado, Florida, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Arterial Hypertension PAH

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Arterial Hypertension PAH

All registered trials for this condition

Pulmonary Hypertension, Interstitial Lung Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.